GUB-UCN2 (Urocortin-2 Analog)

Urocortin 2 is an endogenous 38-amino-acid neuropeptide in the corticotropin-releasing factor family. It binds selectively to CRHR2, one of the two receptors that family signals through, and CRHR2 is expressed in skeletal muscle, heart and vasculature. GUB-UCN2 is Gubra's engineered long-acting version of that peptide, developed in-house and retained rather than partnered out. The company calls it its lead asset.

The reason to pay attention is positional. Nearly every compound in the obesity pipeline works on intake, whether through the incretin receptors, amylin, or the appetite circuits downstream of them. GUB-UCN2 does not touch appetite at all. It acts on the tissue that intake-reducing drugs inadvertently cost their users, which places it in a different category from the rest of the field: a body-composition agent rather than a weight-loss agent.

Gubra announced on 28 July 2026 that the first participant in the first-in-human trial had completed the first visit.^[1] The Phase 1/2a design is unusually broad for a first-in-human study. It enrolls approximately 188 participants across three parts — a single ascending dose component, a multiple ascending dose component, and a multiple-dose component running up to 16 weeks — drawing on both healthy volunteers and people living with obesity, with and without related comorbidities. The trial evaluates GUB-UCN2 as monotherapy and in combination with incretin-based therapy, and it treats muscle volume and muscle function as focal endpoints rather than exploratory extras.

Initial safety, tolerability and pharmacokinetic data from the single-ascending-dose portion are expected in the first half of 2027, with the remaining readouts released sequentially after that. Gubra has scheduled an investor R&D event for 27 October 2026 to set out the development strategy in more detail. The compound is investigational, is not approved in any jurisdiction, and is not commercially available.

CRHR2 belongs to the corticotropin-releasing factor system, which is better known for the stress axis it runs through the related receptor CRHR1. The skeletal-muscle biology is a separate branch of that system and is reasonably well characterised. Urocortin 2 acting at CRHR2 on muscle raises cyclic AMP; downstream, the Akt/mTOR and ERK1/2 pathways drive protein synthesis while expression of the atrophy marker atrogin-1 and the rate of autophagic flux both fall. In overexpression models this combination produces pronounced hypertrophy.^[2]

Gubra describes the effect as reprogramming muscle toward an exercise-like phenotype. That is a fair shorthand for the transcriptional overlap, and it should be read as a statement about shared pathways rather than a claim that the compound reproduces what training does. Exercise engages dozens of signals across multiple tissues; this engages one receptor.

The strategic logic behind the programme needs little unpacking. GLP-1 therapy reliably delivers weight loss, and a meaningful share of that loss is lean tissue. A compound that adds muscle while the incretin removes fat would address the composition problem directly rather than mitigating it through diet and resistance training alone. Gubra's preclinical combination work is built around exactly that pairing.

GUB-UCN2 is the first CRHR2 agonist to reach human trials in obesity, and it targets the part of the problem incretin drugs handle worst. The preclinical body-composition numbers are striking and the trial is better designed than most first-in-human studies. Set against that: no human data at all, headline figures disclosed by the sponsor rather than published, a receptor with cardiovascular expression, and a dose-response relationship that inverts between acute and chronic exposure. The single-ascending-dose readout in the first half of 2027 is the first moment any of it becomes checkable.